Evidence map›Paper›PMID 26456774›Full record

ArticleOncotarget2015

Mechanisms of dihydrotestosterone action on resveratrol-induced anti-proliferation in breast cancer cells with different ERα status.

Yu-Tang Chin, Sheng-Huei Yang, Tung-Cheng Chang, Chun A Changou, Hsuan-Yu Lai, Earl Fu, Wei-Chun HuangFu, Paul J Davis, Hung-Yun Lin, Leroy F Liu

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Androgen signalling in the ovaries and endometrium.Molecular human reproduction · 2023
    Review
  7. Review
  8. Review
  9. Review
  10. Role of natural compounds in preventing and treating breast cancer.Frontiers in bioscience (Scholar edition) · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Beyond the Matrix: The Many Non-ECM Ligands for Integrins.International journal of molecular sciences · 2018
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Yu-Tang ChinTaipei Cancer Center, Taipei Medical University, Taipei, Taiwan.
Sheng-Huei YangPhD Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Tung-Cheng ChangDivision of Colorectal Surgery, Department of Surgery, Taipei Medical University-Shuang-Ho Hospital, New Taipei City, Taiwan.
Chun A ChangouPhD Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Hsuan-Yu LaiTaipei Cancer Center, Taipei Medical University, Taipei, Taiwan.
Earl FuDepartment of Periodontology, School of Dentistry, National Defense Medical Center and Tri-Service General Hospital, Taipei, Taiwan.
Wei-Chun HuangFuTaipei Cancer Center, Taipei Medical University, Taipei, Taiwan.
Paul J DavisPharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, New York, USA.
Hung-Yun LinTaipei Cancer Center, Taipei Medical University, Taipei, Taiwan.
Leroy F LiuTaipei Cancer Center, Taipei Medical University, Taipei, Taiwan.
Taipei Medical University · TWAlbany College of Pharmacy and Health Sciences · USTaipei Medical University-Shuang Ho Hospital · TWTri-Service General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dihydrotestosterone (DHT) has been shown to promote breast cancer growth via different mechanisms. In addition to binding to ERα, the DHT membrane receptor exists on integrin αvβ3. Resveratrol induces p53-dependent apoptosis via plasma membrane integrin αvβ3. Resveratrol and DHT signals are both transduced by activated ERK1/2; however, DHT promotes cell proliferation in cancer cells, whereas resveratrol is pro-apoptotic. In this study, we examined the mechanism by which DHT inhibits resveratrol-induced apoptosis in human ERα positive (MCF-7) and negative (MDA-MB-231) breast cancer cells. DHT inhibited resveratrol-stimulated phosphorylation of Ser-15 of p53 in a concentration-dependent manner. These effects of DHT on resveratrol action were blocked by an ERα antagonist, ICI 182,780, in MCF-7 breast cancer cells. DHT inhibited resveratrol-induced nuclear complex of p53-COX-2 formation which is required p53-dependent apoptosis. ChIP studies of COX-2/p53 binding to DNA and expression of p53-responsive genes indicated that DHT inhibited resveratrol-induced p53-directed transcriptional activity. In addition, DHT did inhibit resveratrol-induced COX-2/p53-dependent gene expression. These results suggest that DHT inhibits p53-dependent apoptosis in breast cancer cells by interfering with nuclear COX-2 accumulation which is essential for stimulation of apoptotic pathways. Thus, the surface receptor sites for resveratrol and DHT are discrete and activate ERK1/2-dependent downstream effects on apoptosis that are distinctive. These studies provide new insights into the antagonizing effects of resveratrol versus DHT, an important step toward better understanding and eventually treating breast cancer. It also indicates the complex pathways by which apoptosis is induced by resveratrol in DHT-depleted and -repleted environments.

Indexed as

ApoptosisBreast NeoplasmsCell Line, TumorCell ProliferationDihydrotestosteroneDrug InteractionsEstrogen Receptor alphaFemaleHumansIntegrin alphaVbeta3MCF-7 CellsPhosphorylationResveratrolSignal TransductionStilbenesDihydrotestosteroneESR1 protein, humanEstrogen Receptor alphaIntegrin alphaVbeta3ResveratrolStilbenesbreast cancerDHTestrogen receptor-αintegrin αvβ3resveratrol

Identifiers

PMID26456774
PMCPMC4742147
OpenAlexW2280524699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.